Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

NCT06745063 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

FED

Sponsor class

Conditions

Obesity
Vascular Health

Interventions

DRUG: Empagliflozin
DRUG: Placebo

Sponsor

VA Office of Research and Development

Collaborators

[object Object]